


Gadolinium retention in the brain



Guerbet | 

Dotarem® is a trade mark of Guerbet
Magnevist® is a trade mark of Bayer

T1w hyperintensities in the Dentate Nucleus (DN) on unenhanced MR images have been reported:

- After repeated injections of **linear GBCAs (L-GBCAs)** ^{1,2,3}
- Caused by **retention of gadolinium in the brain tissue** ³
- In patients with **normal renal function** ^{1,2,3}

Some patients, such as those with brain tumors, multiple sclerosis or breast cancer, may require serial GBCA-enhanced MRI examinations. Gadolinium may accumulate in the brain following repeated injections of L-GBCAs. The clinical consequences of this retention are unknown today.

This brochure gives an overview and latest updates about hyperintensities and gadolinium retention as of January 2018.

TABLE OF CONTENTS

1. HYPERINTENSITIES

- a. Not all GBCAs induce visible brain T1w hyperintensities - clinical evidence ... 4
- b. Why these differences: various molecular structures, various stabilities 6
- c. Selected pieces of evidence 8
- d. Controversies in clinical studies 12

2. GADOLINIUM RETENTION

- a. Hyperintensities are caused by gadolinium retention 14
- b. Gd levels remaining in the body are higher after administration of linear GBCAs compared to macrocyclic GBCAs 16
- c. Presence of Gd associated to macromolecules after injection of linear GBCAs 18

Key abbreviations

SI: Signal Intensity
GBCA: Gadolinium based Contrast Agent
L-GBCA: Linear GBCA
M-GBCA: Macrocyclic GBCA

DN: Dentate Nucleus
GP: Globus Pallidus
MCP: Medium Cerebellar Peduncle
DCN: Deep Cerebellar Nuclei

1. HYPERINTENSITIES

a) Not all GBCAs induce visible brain T1w hyperintensities - clinical evidence

Molecule stability		Macrocyclic GBCAs		
		Ionic	>	Non ionic
		Dotarem® (Gadoteric Acid)	Prohance® (gadoteridol)	Gadovist® (gadobutrol)
Hyperintensities studies	Adults	<ul style="list-style-type: none"> • Radbruch (II) 2015¹ • Radbruch (III) 2016⁴ • Eisele 2016⁵ • Radbruch (IV) 2017⁶ • Bae 2017⁷ • Lee 2017⁸ • Splendiani 2018⁹ • Eisele 2018¹⁰ • Saake 2019¹¹ • Hannoun 2019¹² • Kavak 2019¹³ • Spendiani 2019¹⁴ • Bennani-Baiti 2019¹⁵ 	<ul style="list-style-type: none"> • Kanda (II) 2015²¹ 	<ul style="list-style-type: none"> • Stojanov 2016²⁴ • Radbruch (II) 2015²⁵ • Radbruch (III) 2016⁴ • Cao (I) 2016²⁶ • Radbruch (IV) 2017⁶ • Bae 2017⁷ • Schlemm 2017²⁷ • Langner 2017²⁸ • Müller 2017²⁹ • Bjørnerud 2017³⁰ • Yoo 2018³¹ • Behzadi 2018³² • Moser 2018³³ • Jaulent 2018³⁴ • Kang 2018³⁵ • Moreno 2018³⁶ • Splendiani 2018⁹ • Kelemen 2018³⁷
	Children	<ul style="list-style-type: none"> • Rossi Espagnet 2017¹⁶ • Radbruch (V) 2017¹⁷ • Ryu 2018¹⁸ • Pozeg 2019¹⁹ • Topcuoglu 2019²⁰ 	<ul style="list-style-type: none"> • Young 2018^{22, 23} 	<ul style="list-style-type: none"> • Young 2018²² • Renz 2018³⁸ • Bhargava 2018³⁹

■ No hyperintensities found
 ■ Non-conclusive or questionable study design*
 ■ Hyperintensities found

Prohance® is a trade mark of Bracco - Gadovist® is a trade mark of Bayer.

The clinical studies listed in the table below evaluate the correlation between cumulative doses of various GBCAs and presence of hyperintensities in the brain on unenhanced T1-weighted images. The table includes retrospective studies with patients who received: 1/ repeated injections of a single GBCA during the study period, 2/ repeated injections of a single class of GBCA (macrocytic or linear) during the study period, or 3/ subsequent injections of different GBCAs for which the period of injection of each GBCA is identified and studied.

Linear GBCAs			
Ionic		Non ionic	
Primovist® (gadoteric acid disodium)	Magnevist® (gadopentetate dimeglumine)	Multihance® (gadobenate dimeglumine)	Omniscan™ (gadodiamide)
<ul style="list-style-type: none"> • Kahn 2017⁴⁰ • Ichikawa 2017⁴¹ • Conte 2017⁴² • Holesta 2018⁴³ • Kim 2018⁴⁴ 	<ul style="list-style-type: none"> • Kanda (I) 2014⁴⁵ • Radbruch (I) 2015¹ • Kanda (II) 2015²¹ • Radbruch (II) 2015²⁵ • Cao (I) 2016²⁶ • Tanaka 2016⁴⁶ • Bae 2017⁷ • Schlemm 2017²⁷ • Kuno 2017⁴⁷ • Behzadi 2018³² • Tamrazi 2018⁴⁸ 	<ul style="list-style-type: none"> • Weberling 2015² • Ramalho (I) 2015⁵² • Ramalho (II) 2016⁵³ • Bolles 2018⁵⁴ 	<ul style="list-style-type: none"> • Kanda (I) 2014⁴⁵ • Errante 2014⁵⁷ • McDonald 2015³ • Ramalho (I) 2015⁵² • Quattrocchi 2015⁵⁸ • Ramalho (II) 2016⁵³ • Tanaka 2016⁴⁶ • Bae 2017⁷ • Ichikawa 2017⁴¹ • Marie 2018⁵⁹ • Quattrocchi 2018⁶⁰ • Koiso 2019⁶¹ • Zivadinov 2019⁶²
	<ul style="list-style-type: none"> • Hu 2016⁴⁹ • Flood 2017⁵⁰ • Renz 2018³⁸ • Flood 2019⁵¹ 	<ul style="list-style-type: none"> • Schneider 2017⁵⁵ • Kinner 2018⁵⁶ 	<ul style="list-style-type: none"> • Young 2018^{22, 23}


* Stojanov 2016²⁴: no visible hyperintensities and absence of control group. The results were questioned by Cao et al. 2016²⁶, Radbruch et al. 2015²⁵ and Runge 2015⁶³.
 Ramalho 1⁵² & II⁵³, 2015 & 2016: studies design questioned on the number of injections and area of normalization.
 Ichikawa⁴¹ & Conte⁴² 2017: studies design questioned on the volume administered to patients, lower than Kahn 2017⁴⁰.
 Rossi Espagnet 2017¹⁶: no visible hyperintensities. The results were questioned by two letters to the editor (Lancelot 2017⁵⁴ and Radbruch 2017⁶⁵).
 Splendiani 2018⁹: the differences were not statistically significant across the entire patient population.
 Bjørnerud 2017³⁰: results questioned on the high windowing, the enhancement observed (located also outside the DN), the similarity pre/post in enhancement, the decrease of noise in the full image, the timing between injections too short to allow full wash-out of the Gd complex.
 Schneider 2017⁵⁵: study design questioned on the dose (half dose was injected instead of full dose).

Primovist® is a trade mark of Bayer - Multihance® is a trade mark of Bracco - Omniscan® is a trade mark of GE Healthcare.

b) Why these differences: various molecular structures, various stabilities⁶⁶


Kinetic stability: M-GBCAs > L-GBCAs

- The kinetic stability represents the speed of free gadolinium release from the original GBCAs complex.
- The lower the kinetic stability, the shorter the dissociation half-life, thus the faster the release of free gadolinium.
- It is typically measured in vitro under very acidic conditions (pH 1).⁶⁷
- At a pH>5, M-GBCAs demonstrate a dissociation half-life of 36-65 years in comparison to 5-7 days for L-GBCAs.⁶⁷



Thermodynamic stability: ionic GBCAs > non ionic GBCAs

- The thermodynamic stability is another parameter measuring the propensity to release gadolinium.
- The higher the thermodynamic stability, the lower the quantity of free gadolinium released.




Stability of GBCAs in human serum⁶⁷

KEY POINTS

- Non-ionic L-GBCAs: free gadolinium (Gd^{3+}) released ~ 10 times higher than ionic linear GBCAs
- Ionic L-GBCAs: slower but continuous release of Gd^{3+}
- M-GBCAs: no release of Gd^{3+}

Comparison of the amounts of gadolinium released

From 1 mmol/L solutions
In native human serum from healthy volunteers
At 37°C during an incubation period of 15 days



This study suggests that the molecular structure of the GBCAs can impact their stability.

The graph colors shown on this page have been adapted for presentation purpose.

Why these
differences ?

c) Selected pieces of evidence

Comparison between a M-GBCA (Dotarem®) and L-GBCAs (Magnevist® & Multihance®) - clinical study

Two clinical studies investigated the hyperintensities in the brains of patients with normal renal function.^{1,2}


KEY POINTS

- Repeated administrations of Dotarem® did not induce hyperintensities in the Dentate Nucleus (DN) and Globus Pallidus (GP)
- Same level of hyperintensities in the DN following repeated administrations of the L-GBCAs Multihance® and Magnevist®

	Radbruch ¹ study	Weberling ² study
Materials & methods	<ul style="list-style-type: none">• Retrospective comparison of Dotarem® and Magnevist®.• 2 groups of 50 patients received at least 6 administrations of Dotarem® or Magnevist®.• Larger dose of Dotarem® per examination was used (mean dose: 27.07 mL) compared to Magnevist® (mean dose: 19.62 mL).	<ul style="list-style-type: none">• Retrospective assessment of Multihance® and comparison with Dotarem® and Magnevist® with the results from the Radbruch¹ study.• 50 patients received an average of 7.7 CE-MRIs with Multihance®.
Conclusion	<ul style="list-style-type: none">• "This study indicates that an SI increase in the DN and GP on T1-weighted images is caused by serial application of the linear GBCA gadopentetate dimeglumine but not by the macrocyclic GBCA gadoterate meglumine."	<ul style="list-style-type: none">• "The present study found an increase in SI in the DN after serial injections of gadobenate dimeglumine."• "Compared with previously published data, the difference in SI increase between gadopentetate dimeglumine and gadobenate dimeglumine was not significant for the DN-to-Pons ratio."


Graph of the mean DN-to-Pons SI ratio differences between the last and first MRIs²

Adapted from table 1, Weberling et al. 2015²




Unenhanced T1w MRI scans


6 administrations of Dotarem®¹



6 administrations of Magnevist®¹



15 administrations of Multihance®²



Comparison between a M-GBCA (Dotarem®) with L-GBCAs Preclinical study⁶⁸


Findings of clinical studies were confirmed by several studies conducted on rats, including Robert et al. 2016.⁶⁸

KEY POINTS

- L-GBCAs: presence of T1 hyperintensities in the Deep Cerebellar Nuclei (DCN)
- Dotarem® or saline: no change over 10 weeks

Materials & methods	<ul style="list-style-type: none">• The healthy rats received 20 intravenous injections of 0.6 mmol Gd/kg of one exclusive GBCA.• 4 injections per week performed, for 5 weeks.• T1-weighted MRI performed before injection and once a week during the 5 weeks of injections and for another 4 additional weeks after contrast period.• Blinded image analysis of MRI scans, including signal intensity measurements in the DCN.
------------------------	---

Signal intensity after repeated injections of each GBCA



Another study⁶⁹ conducted on rats evaluated the T1w hyperintensities in the brain, up to 24 days, after repeated administration of L-GBCAs (Omniscan™, Magnevist®, Multihance®) and M-GBCAs (Dotarem®, Gadovist®). This study found:

- **Hyperintensities in the DCN after repeated administration of L-GBCAs,**
- **No hyperintensities in the DCN for the M-GBCAs.**

d) Controversies in clinical studies

Various studies about hyperintensities have been released, using different protocols. Protocols chosen could impact the sensitivity of a study and its results.

Number of injections & volume injected	Area of normalization
<ul style="list-style-type: none">• At least 6 injections are needed to have a clear hyperintensity effect.^{57, 58, 70}• If the volume and/or the number of injections are too low, hyperintensities in the brain may not be seen with some L-GBCAs.^{41, 42, 52, 53}• For instance, in the Ramalho studies,^{52, 53} the number of Multihance® injections was below 6, and the two studies concluded repeated injections of Multihance® do not trigger hyperintensities.• However, other studies^{2, 54} concluded repeated injections of the same product lead to presence of hyperintensities in the brain. In these studies, the patients received more than 6 injections of Multihance®.	<ul style="list-style-type: none">• If the area of normalization is not appropriately chosen, it may also influence the results of a study.• McDonald et al.³ demonstrated the Pons is the area where there is the least gadolinium deposition.• Data from the Cao study²⁶ showed that the Pons is more sensitive than the Cerebellar Peduncle (CP).

Age effect in children

- A study demonstrated that brain T1 is significantly related to age. Indeed, in children, the brain T1 Signal Intensity (SI) varies with the age.⁷¹
- In hyperintensities studies conducted in children, this variation may influence the results. Comparison to a control group or use of specific statistics is required.
- For instance, in the Rossi Espagnet study,¹⁶ the SI increase calculated after repeated injections of Dotarem® may be related to brain maturation. Indeed, no visible hyperintensities are seen on the MR scans published in the study. Moreover, two other studies using specific statistics or a control group demonstrated the absence of hyperintensities in the pediatric brain after repeated injections of Dotarem®.¹⁷
- Pozeg¹⁹ et al. demonstrated that repeated exposure to gadoterate meglumine was not associated with brain hyperintensity in the pediatric patients, **whereas age importantly contributed to the signal intensity changes in several deep brain nuclei.**
- Flood⁵¹ et al. exhibited that increased age correlates with increased signal intensity in all brain locations, except the frontal gray matter, irrespective of sex. The biologic mechanisms may be related to chronologic changes in myelin density, synaptic density, and water content. Establishing age-dependent signal intensity parameters in the structurally normal pediatric brain enhance gadolinium-deposition research by providing an improved understanding of the confounding effect of age.

2. GADOLINIUM RETENTION

a) Hyperintensities are caused by gadolinium retention


Post-mortem study

The study McDonald et al.³ detected retention of gadolinium in patients presenting hyperintensities in the brain.

KEY POINTS


- **Neuronal tissue deposition of gadolinium** appears to be cumulative over a patient's lifetime:
 - After injections of a **single non-ionic L-GBCA, Omniscan™**
 - In patients with **normal renal function**

MR signal intensity changes



Gadolinium detection


Of cadaveric tissues, with mass spectrometry



Cumulative intravenous gadodiamide dose (mL)

Materials & methods	<ul style="list-style-type: none"> Comparative study between post-mortem neuronal tissue samples from 13 patients who underwent at least 4 GBCA-enhanced brain MRIs with those from 10 patients who did not receive any GBCA (control group). Analysis performed with inductively coupled plasma mass spectrometry (ICP-MS), transmission electron microscopy, and light microscopy.
Conclusion	<ul style="list-style-type: none"> Patients exposed to multiple doses of L-GBCA: measurable quantities of gadolinium deposited in their brain tissues ranging from 0.1 to 58.8 μg gadolinium per gram of tissue. Control group: no detectable levels of gadolinium. <i>"Our findings suggest that intravenous administration of GBCA is associated with dose-dependent deposition in neuronal tissues that is unrelated to renal function, age, or interval between exposure and death."</i>

Tissue localization and cellular response to gadolinium retention



A, B: X-ray spectra are also shown for selected electron-dense foci (arrow); gadolinium peaks in spectra are indicated by red overlay.
C = carbon, Cs = cesium, Cu = copper, Gd = gadolinium,
O = oxygen, Os = osmium, Pb = lead, Ti = titanium, V = vanadium.

Hyperintensities
are caused by
Gd retention

b) Gd levels remaining in the body are higher after administration of linear GBCAs compared to macrocyclic GBCAs


KEY POINT

- In both clinical and preclinical studies, levels of gadolinium retained after administration of M-GBCAs are significantly lower than after L-GBCAs

Clinical study results - example⁷²

Median ratio of amount of gadolinium retained in the brain

Per gram of tissue per millimole of administered dose




- The study suggests the macrocyclic GBCA Prohance® is retained "at a ratio greater than 20 times lower compared with the Group 1 agent" Omniscan™.

The graphs colors shown on this page have been adapted for presentation purpose.

Preclinical study - example⁶⁸

Total gadolinium concentration

In nmol/g of tissue for cerebellum
Individual values, mean, and SD are given
Measured with inductively coupled mass spectrometry



- "Repeated administrations of the linear GBCAs gadodiamide, gadobenate dimeglumine, and gadopentetate dimeglumine to healthy rats were associated with progressive and significant T1 signal hyperintensity in the DCN, along with Gd deposition in the cerebellum. This is in contrast with the macrocyclic GBCA gadoterate meglumine for which no effect was observed."

Gd levels remaining
are higher after
L-GBCA

c) Presence of Gd associated to macromolecules after injection of linear GBCAs

Gadolinium retention studies retrospectively conducted in humans present several limitations. Further research is needed to fully understand the wash-out kinetics of GBCAs and if gadolinium remains chelated over time. Preclinical studies help providing some answers to limitations met in clinical studies.

Form & kinetics of gadolinium in preclinical data after 24 days ⁷³

A bioanalytical study in rat brain tissue was initiated to investigate whether the residual Gd is present as intact GBCA or in other chemical forms after 24 days.

KEY POINTS


- Presence of **intact complex of gadolinium** (GBCA) for **all contrast agents**
- **Only for L-GBCAs:** presence of **Gd associated to macromolecules, highly suggestive of dechelation**
- **Only for M-GBCAs:** **absence of Gd associated to macromolecules**, demonstrating **higher stability**

Materials & methods


- 6 groups of 10 rats – 10 IV injections of GBCA at 2.5 mmol/kg/day over 2 weeks
- Sacrifice on day 3 and day 24 after the last injection
- Collection and homogeneization of cerebrum, cerebellum and pons
- Quantification and characterization of Gd in the soluble tissue fraction

Chromatograms of the soluble fractions of cerebellum homogenates from rats after 3 days and 24 days

L-GBCAs



M-GBCAs



d = days

Presence of Gd associated to macromolecules after L-GBCAs

Form & kinetics of gadolinium in preclinical data after 1 year⁷⁴

A study was initiated to compare the long-term brain elimination kinetics and gadolinium species in healthy rats after repeated injections of L-GBCA OmniscanTM or M-GBCA Dotarem[®].

KEY POINTS


- After repeated injections of the **L-GBCA OmniscanTM**, a large portion of Gd was **trapped** with 75% retained in the cerebellum after 1 year, and with **binding of soluble Gd to macromolecules**
- After repeated injections of **M-GBCA Dotarem[®]**, **only traces of the intact chelated Gd** were observed, with **time-dependent clearance**

Materials & methods	<ul style="list-style-type: none">• Animals received 5 doses of 2.4 mmol Gd/kg over 5 weeks• Rats were randomized to 7 groups with 0, 1, 2, 3, 4, 5, and 12 months (M0 to M12) of injection free period before sacrifice (n=10/product/time-point)• Brain sections were sampled to dose total gadolinium• Right half of the cerebellum at M1, M3, M5 and M12 was used for gadolinium speciation studies
------------------------	--


M = month

Chromatograms of the soluble fraction of cerebellum extracts after repeated injections of Dotarem® and Omniscan™ during 12 months of follow-up (Examples of SEC-ICP-MS)

Omniscan™



Dotarem®



M = months

Presence of Gd associated to macromolecules after L-GBCAs

CONCLUSION

➡ Chemical stability⁶⁶

The chemical stability of GBCAs differs according to their structure. The dissociation half-lives demonstrate that M-GBCAs are more stable than L-GBCAs.

➡ In vitro stability in physiological conditions⁶⁷

Over a period of 15 days in human serum and at pH 7.4, Frenzel et al. 2008 showed L-GBCAs dissociate from their original compound whereas M-GBCAs do not (below LOQ).

➡ No Brain Hyperintensities in normal renal function in adults and pediatric patients⁶⁹

No visible brain hyperintensities related to dechelated Gd following repeated injections of M-GBCAs have been reported, contrary to L-GBCAs.

➡ Rapid Gadolinium Washout and still chelation after 1 year^{69, 73, 74}

As any drugs, there is a presence in the brain and cerebellum of all GBCAs after repeated intravenous administration. This presence is explained by a standard prolonged washout of the chelated form of the GBCAs. It has been demonstrated in a preclinical study⁵¹ that Dotarem® has rapid and total washout in 5 months and remains chelated even after one year following the last injection. However, in the same study, following repeated injections of the L-GBCA Omniscan™, presence of Gd associated to macromolecules within the first month was demonstrated, highly suggestive of dechelation.

➡ Clinical consequences unknown

Today, it remains unknown if gadolinium deposition could lead to potential long-term toxicity.

References

- 1 Radbruch A et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. *Radiology*. 2015 Jun;275(3):783-91.
- 2 Weberling LD et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. *Invest Radiol*. 2015 Nov;49:743-8.
- 3 McDonald RJ et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. *Radiology*. 2015 Jun;275(3):772-82.
- 4 Radbruch A et al. Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents. *Invest Radiol*. 2016 Nov;51(11):683-690.
- 5 Eisele P et al. Lack of increased signal intensity in the dentate nucleus after repeated administration of a macrocyclic contrast agent in multiple sclerosis: An observational study. *Medicine (Baltimore)*. 2016 Sep;95(39):e4624.
- 6 Radbruch A et al. No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. *Radiology*. 2017 Mar;282(3):699-707.
- 7 Bae S et al. Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model. *Eur Radiol*. 2017 Aug;27(8):3353-61.
- 8 Lee JY et al. Up to 52 administrations of macrocyclic ionic MR contrast agent are not associated with intracranial gadolinium deposition: Multifactorial analysis in 385 patients. *PLoS One*. 2017 Aug 31;12(8):e0183916. eCollection 2017.
- 9 Splendiani A et al. Reply to: RE: effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain-a retrospective study in 158 multiple sclerosis (MS) patients. *Radiol Med*. 2018 Jul;123(7):535-537.
- 10 Eisele P et al. Lack of T1 hyperintensity in the dentate nucleus after 15 administrations of a macrocyclic contrast agent in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2018 Mar; 89:324-326.
- 11 Saake M et al. MRI Brain Signal Intensity and Relaxation Times in Individuals with Prior Exposure to Gadobutrol. *Radiology* 2019; 290:659-668.
- 12 Hannoun S et al. Gadoterate Meglumine Administration in Multiple Sclerosis has no Effect on the Dentate Nucleus and the Globus Pallidus Signal Intensities. *Acad Radiol*. 2019 Oct;26(10):e284-e291.
- 13 Kavak RP et al. Increased signal intensity in the unenhanced T1-weighted magnetic resonance in the brain after repeated administrations of a macrocyclic-ionic gadolinium-based contrast agent. *J Surg Med*. 2019 Jul; 3(7):507-511.
14. Splendiani, A., Corridore, A., Torlone, S. et al. Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no?. *Insights Imaging*. 2019 Sep 4;10(1):82.
15. Bannani-Baiti B et al. Evaluation of 3.0-T MRI Brain Signal after Exposure to Gadoterate Meglumine in Women with High Breast Cancer Risk and Screening Breast MRI. *Radiology*. 2019 Dec;293(3):523-530.
- 16 Rossi Espagnet MC et al. Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. *Pediatr Radiol*. 2017 Sep;47(10):1345-52. Epub 2017 May 19.

- 17 Radbruch A et al. Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent. *Radiology*. 2017 Jun;283(3):828-36.
- 18 Ryu YJ et al. Pediatric Brain: Gadolinium Deposition in Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images Is Dependent on the Type of Contrast Agent. *Invest Radiol*. 2018 Apr;53(4):246-255.
- 19 Pozeg P et al. Age, But Not Repeated Exposure to Gadoterate Meglumine, Is Associated With T1- and T2- Weighted Signal Intensity Changes in the Deep Brain Nuclei of Pediatric Patients. *Invest Radiol*. 2019 Sep;54(9):537-548.
- 20 Topcuoglu ED et al. Does Gadoterate Meglumine Cause Gadolinium Retention in the Brain of Children? A Case-Control Study. *J. Magn. Reson. Imaging* 2019 10.1002/jmri26954
- 21 Kanda T et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. *Radiology*. 2015 Jun;275(3):803-9.
- 22 Young JR et al. Gadolinium deposition within the paediatric brain: no increased intrinsic T1-weighted signal intensity within the dentate nucleus following the administration of a minimum of four doses of the macrocyclic agent gadobutrol. *Eur Radiol*. 2018 Nov;28(11):4882-4889.
- 23 Young JR et al. Gadolinium Deposition within the Pediatric Brain: No Increased Intrinsic T1-Weighted Signal Intensity within the Dentate Nucleus following the Administration of a Minimum of 4 Doses of the Macrocyclic Agent Gadoteridol. *AJNR Am J Neuroradiol*. 2018 Sep;39(9):1604-1608.
- 24 Stojanov DA et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. *Eur Radiol*. 2016 Mar;26(3):807-15.
- 25 Radbruch A et al. High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. *Invest Radiol*. 2015 Dec;50(12):805-10.
- 26 Cao Y et al. Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. *AJR Am J Roentgenol*. 2016 Feb;206(2):414-9.
- 27 Schlemm L et al. Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients. *Mult Scler*. 2017 Jun;23(7):963-72.
- 28 Langner S et al. Repeated intravenous administration of gadobutrol does not lead to increased signal intensity on unenhanced T1-weighted images-a voxel-based whole brain analysis. *Eur Radiol*. 2017 Sep;27(9):3687-93. Epub 2017 Mar 13.
- 29 Müller A et al. Brain relaxometry after macrocyclic Gd-based contrast agent. *Clin Neuroradiol*. 2017 Dec;27(4):459-468. Epub 2017 Jul 24.
- 30 Bjørnerud A et al. Signal enhancement of the dentate nucleus at unenhanced mr imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: an observational study. *Radiology*. 2017 Nov;285(2):434-444. Epub 2017 Sep 8.
- 31 Yoo RE et al. Evaluation of gadolinium retention after serial administrations of a macrocyclic gadolinium-based contrast agent (gadobutrol): a single-institution experience with 189 patients. *Invest Radiol*. 2018 Jan;53(1):20-25. Epub 2017 Jul 24.
- 32 Behzadi AH et al. Dentate Nucleus Signal Intensity Decrease on T1-weighted MR Images after Switching from Gadopentetate Dimeglumine to Gadobutrol. *Radiology*. 2018 Jun;287(3):816-823.

- 33 Moser FG et al. High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted MR Images: Comparison between Gadobutrol and Linear Gadolinium-Based Contrast Agents. *AJNR Amj Neuroradiol* 2018;39:421-26.
- 34 Jaulent P et al. Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus? *Eur Radiol*. 2018 Jun; 105(2018):204-208.
- 35 Kang KM et al. T1 Shortening in the Globus Pallidus after Multiple Administrations of Gadobutrol: Assessment with a Multidynamic Multiecho Sequence. *Radiology*. 2018 Apr;287(1):258-266.
- 36 Moreno J et al. High Signal Intensity in the Dentate Nucleus on Unenhanced T1-Weighted MR Images in Melanoma Patients Receiving Macrocyclic Gadolinium-Based Contrast. *J Radiol Diagn Methods* 2018;1:101.
- 37 Kelemen P et al. T1-weighted Grey Matter Signal Intensity Alterations After Multiple Administrations of Gadobutrol in Patients with Multiple Sclerosis, Referenced to White Matter. *Sci Rep*. 2018 Nov 15;8(1):16844.
- 38 Renz DM et al. Comparison of unenhanced T1-weighted signal intensities within the dentate nucleus and the globus pallidus after serial applications of gadopentetate dimeglumine versus gadobutrol in a pediatric population. *Invest Radiol*. 2018 Feb;53(2):119-127. Epub 2017 Oct 2.
- 39 Bhargava R et al. Multiple Administrations of Gadobutrol in the Pediatric Brain: No Change in T1 Signal at MRI. *Radiology*. 2018; 289:204-209.
- 40 Kahn J et al. Is there long-term signal intensity increase in the central nervous system on T1-weighted images after MR imaging with the hepatospecific contrast agent gadoxetic acid? a cross-sectional study in 91 patients. *Radiology*. 2017 Mar;282(3):708-16.
- 41 Ichikawa S et al. Contrast agent-induced high signal intensity in dentate nucleus on unenhanced T1-weighted images: comparison of gadodiamide and gadoxetic acid. *Invest Radiol*. 2017 Jul;52(7):389-95.
- 42 Conte G et al. Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study. *Eur Radiol*. 2017 Oct;27(10):4372-78. Epub 2017 Mar 29.
- 43 Holesta M et al. Gadoxetate disodium, a modern hepatospecific MRI contrast agent: Indirect signs for gadolinium deposition in the brain structures with signal intensity increase after intravenous application. *Neurol India*. 2018 Nov-Dec;66(6):1771-1775.
- 44 Kim SY et al. Gadolinium deposition after the application of the hepatospecific gadolinium-based contrast agent gadoxetate disodium. *Eur J Intern Med*. 2018 Jan;47:e9-e11.
- 45 Kanda T et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. *Radiology*. 2014 Mar;270(3):834-41.
- 46 Tanaka M et al. Increased signal intensity in the dentate nucleus of patients with multiple sclerosis in comparison with neuromyelitis optica spectrum disorder after multiple doses of gadolinium contrast. *Eur Neurol*. 2016;75(3-4):195-8.
- 47 Kuno H et al. Global and regional brain assessment with quantitative MR imaging in patients with prior exposure to linear gadolinium-based contrast agents. *Radiology*. 2017 Apr;283(1):195-204. Epub 2016 Oct 31.
- 48 Tamrazi B et al. Changes in Signal Intensity of the Dentate Nucleus and Globus Pallidus in Pediatric Patients: Impact of Brain Irradiation and Presence of Primary Brain Tumors Independent of Linear Gadolinium-based Contrast Agent Administration. *Radiology*. 2018 May;287(2):452-460.

- 49 Hu HH et al. Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. *Pediatr Radiol*. 2016 Oct;46(11):1590-8. Epub 2016 Jun 9.
- 50 Flood TF et al. Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. *Radiology*. 2017 Jan;282(1):222-228. Epub 2016 Jul 28.
- 51 Flood TF et al. Age-Dependent Signal Intensity Changes in the Structurally Normal Pediatric Brain on Unenhanced T1-Weighted MR Imaging. *AJNR*. 2019 40(11) 1824-1828.
- 52 Ramalho J et al. High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. *Radiology*. 2015 Sep;276(3):836-44.
- 53 Ramalho J et al. Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide. *Eur Radiol*. 2016 Nov;26(11): 4080-4088. Epub 2016 Feb 24.
- 54 Bolles GM et al. Development of high signal intensity within the globus pallidus and dentate nucleus following multiple administrations of gadobenate dimeglumine. *Am J Neuroradiol*. 2018 Jan 18. [Epub ahead of print].
- 55 Schneider GK et al. T1 signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease. *Am J Neuroradiol*. 2017 Sep;38(9):1799-806. Epub 2017 Jun 22.
- 56 Kinner S et al. Deep Brain Nuclei T1 Shortening after Gadobenate Dimeglumine in Children: Influence of Radiation and Chemotherapy. *AJNR Am J Neuroradiol*. 2018 Jan;39(1):24-30.
- 57 Errante Y et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. *Invest Radiol*. 2014 Oct;49(10):685-90.
- 58 Quattrocchi CC et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. *Invest Radiol*. 2015 Jul;50(7):470-2.
- 59 Marie GPO et al. Spatiotemporal Pattern of Gadodiamide-Related T1 Hyperintensity Increase Within the Deep Brain Nuclei. *Invest Radiol*. 2018 Dec;53(12):748-754.
- 60 Quattrocchi CC et al. Effect of Age on High T1 Signal Intensity of the Dentate Nucleus and Globus Pallidus in a Large Population Exposed to Gadodiamide. *Invest Radiol*. 2018 Apr;53(4):214-222.
- 61 Koiso T et al. Signal intensity increases in dentate nucleus/globus pallidus/pulvinar on unenhanced T1WI MR images after multiple examinations with gadodiamide. *Neuroradiol J*. 2019 Jun;32(3):215-224.
- 62 Zivadinov R et al. Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. *Neurology*. 2019 Aug 6;93(6):e611-e623.
- 63 Runge VM. Macrocyclic versus linear gadolinium chelates. *Invest Radiol*. 2015 Dec;50(12):811.
- 64 Lancelot E et al. Lack of evidence of a relationship between magnetic resonance signal intensity changes in the globus pallidus and dentate nucleus, and repeated administrations of gadoterate meglumine in children. *Pediatr Radiol*. 2017 Nov;47(12):1692-93. Epub 2017 Sep 9.
- 65 Radbruch A & Quattrocchi CC. Interpreting signal-intensity ratios without visible T1 hyperintensities in clinical gadolinium retention studies. *Pediatr Radiol*. 2017 Nov;47(12):1688-1689. Epub 2017 Sep 15.

- 66 Port M et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. *Biometals*. 2008 Aug;21(4):469-90. Epub 2008 Mar 15.
- 67 Frenzel T et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. *Invest. Radiol*. 2008 Dec;43(12):817-28.
- 68 Robert P et al. Linear gadolinium-based contrast agents are associated with brain gadolinium retention in healthy rats. *Invest Radiol*. 2016 Feb;51(2):73-82.
- 69 Jost G et al. Signal increase on unenhanced T1-weighted images in the rat brain after repeated, extended doses of gadolinium-based contrast agents: comparison of linear and macrocyclic agents. *Invest Radiol*. 2016 Feb;51(2):83-9.
- 70 Adin ME et al. Hyperintense dentate nuclei on T1-weighted MRI: relation to repeat gadolinium administration. *Am J Neuroradiol*. 2015 Oct;36(10):1859-65.
- 71 Steen RG, Schroeder J. Age-related changes in the pediatric brain: proton T1 in healthy children and in children with sickle cell disease. *Magn Reson Imaging*. 2003 Jan;21(1):9-15.
- 72 Murata N et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. *Invest Radiol*. 2016 Jul;51(7):447-53.
- 73 Frenzel T et al. Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. *Invest Radiol*. 2017 Jul;52(7):396-404.
- 74 Robert P et al. One-year Retention of Gadolinium in the Brain: Comparison of Gadodiamide and Gadoterate Meglumine in a Rodent Model. *Radiology* 2018; 288:424-433.

Dotarem®: gadoteric acid
Gadovist®: gadobutrol
Prohance®: gadoteridol
Multihance®: gadobenate dimeglumine
Magnevist®: gadopentetate dimeglumine
Omniscan™: gadodiamide
Primovist®: gadoxetic acid disodium

DOTAREM 0.5 mmol/mL, solution for injection. **Composition:** For 100 mL of solution: active ingredient: Gadoteric Acid 27.932 g corresponding to: DOTA 20.246 g corresponding to gadolinium oxide 9.062 g. **Indications (*):** Medicinal product for diagnostic use only: Magnetic Resonance Imaging for cerebral and spinal disease, diseases of the vertebral column, and other whole-body pathologies (including angiography). Dotarem should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI). **Posology and method of administration:** The recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg in adults and children. The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose should be calculated based on the patient's body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section. In angiography, depending on the results of the examination being performed, a second injection may be administered during the same session if necessary. Angiography with Gadoteric acid is not recommended in children (0-18 years). In Encephalic and spinal MRI, in some exceptional cases, as in the confirmation of isolated metastasis or the detection of leptomeningeal tumours, a second injection of 0.2 mmol/kg may improve tumor characterisation and facilitate therapeutic decision making. For patients with impaired renal function and paediatric population (0-18 years) more than one dose should not be used during a scan, injections should not be repeated unless the interval between injections is at least 7 days. The product must be administered by strict intravenous injection. Depending on the amount of gadoteric acid to be given to the child, it is preferable to use gadoteric acid vials with a single use syringe of a volume adapted to this amount in order to have a better precision of the injected volume. In neonates and infants the required dose should be administered by hand. **Contraindications:** Hypersensitivity to gadoteric acid, to meglumine or to any medicinal products containing gadolinium. **Special warnings and precautions for use:** Dotarem must not be administered by subarachnoid (or epidural) injection. The usual precaution measures for MRI examination should be taken such as exclusion of patients with pacemakers, ferromagnetic vascular clips, infusion pumps, nerve stimulators, cochlear implants or suspected intracorporal metallic foreign bodies, particularly in the eye. **General particulars corresponding to all gadolinium contrast agents:** All gadolinium based contrast media can cause minor or major hypersensitivity reactions that can be life-threatening. These can occur immediately (within 60 minutes) or be delayed (within 7 days) and are often unpredictable. Because of the risk of major reactions, emergency resuscitation equipment should be available for immediate use. Hypersensitivity reactions can be aggravated in patients on betablockers and particularly in the presence of bronchial asthma. These patients may be refractory to standard treatment of hypersensitivity reactions with beta agonists. Impaired renal function: Prior to administration of gadoteric acid, it is recommended that all patients are screened for renal dysfunction by obtaining laboratory tests. There have been reports of Nephrogenic Systemic Fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 mL/min/1.73 m²). As there is a possibility that NSF may occur with Dotarem, it should

only be used in these patients after careful consideration. CNS disorders: As with other contrast agents containing gadolinium, special precautions should be taken in patients with a low seizure threshold. Precautionary measures, e.g. close monitoring, should be taken. All equipment and drugs necessary to counter any convulsions which may occur must be made ready for use beforehand. **Interactions with other medicinal products and other forms of interaction:** No interactions with other medicinal products have been observed. Formal drug interaction studies have not been carried out. **Fertility, pregnancy and lactation:** Gadoteric acid should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteric acid. Continuing or discontinuing breast feeding for a period of 24 hours after administration of gadoteric acid, should be at the discretion of the doctor and lactating mother. **Effects on ability to drive and use machines:** No studies on the effects on the ability to drive and use machines have been performed. Ambulant patients while driving vehicles or operating machinery should take into account that nausea may incidentally occur. **Undesirable effects:** Uncommon ($\geq 1/1000$ to $< 1/100$): hypersensitivity, headache, dysgeusia, dizziness, somnolence, paraesthesia (including burning sensation), hypotension, hypertension, nausea, abdominal pain, rash, feeling hot, feeling cold, asthenia, injection site reactions (extravasation, pain, discomfort, oedema, inflammation, coldness). Rare ($\geq 1/10\,000$ to $< 1/1\,000$): anxiety, presyncope, eyelid edema, palpitations, sneezing, throat tightness, vomiting, diarrhea, salivary hypersecretion, Urticaria, pruritus, hyperhidrosis, chest pain, chills. Very rare ($< 1/10\,000$): anaphylactic reaction, anaphylactoid reaction, agitation, coma, convulsion, syncope, tremor, parosmia, conjunctivitis, ocular hyperaemia, vision blurred, lacrimation increased, tachycardia, cardiac arrest, arrhythmia, bradycardia, flushing, pallor, vasodilatation, hot flush, cough, dyspnoea, nasal congestion, respiratory arrest, bronchospasm, throat irritation, laryngospasm, pharyngeal oedema, dry throat, pulmonary oedema, erythema, angioedema, eczema, muscle cramps, muscular weakness, back pain, arthralgia, malaise, chest discomfort, pyrexia, face oedema, injection site necrosis (in case of extravasation), phlebitis superficial, decreased oxygen saturation, Not known : nephrogenic systemic fibrosis. **Overdose:** Gadoteric acid can be removed by haemodialysis. However there is no evidence that haemodialysis is suitable for prevention of nephrogenic systemic fibrosis. **Please note:** The peel-off tracking label on the vials or syringes should be stuck onto the patient record to enable accurate recording of the gadolinium contrast agent used. The dose used should also be recorded. If electronic patient records are used, the name of the product, the batch number and the dose should be entered into the patient record. **Pharmacological properties:** Pharmacotherapeutic group: paramagnetic contrast media for MRI, ATC code: V08CA02. **Presentation (*):** 5, 10, 15, 20, 60 & 100 mL in vial (glass) and 10, 15 & 20 mL in a pre-filled syringe (glass). **Marketing authorization holder: (*)** **Information:** Guerbet - BP 57400 - F-95943 Roissy CdG cedex – FRANCE. Tel: 33 (0) 1 45 91 50 00. **Date of revision of this document:** February 2018

For current and complete prescribing information refer to the package insert and/or contact your local Guerbet organization. (*) Indications, presentations and marketing authorization holder may differ from country to country.

Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

This brochure is not intended for US/UK healthcare professionals.

Notes

